Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- ChecktodayChange DetectedThe page has removed a citation for a study on Duvelisib in patients with refractory indolent non-Hodgkin lymphoma, which has been replaced with the same citation without the erratum note.SummaryDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version v2.15.0 to v2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant content changes, including the removal of detailed descriptions of a Phase 2 clinical trial for duvelisib in treating indolent non-Hodgkin lymphoma, while a new version number has been added.SummaryDifference18%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.